论文部分内容阅读
1名80岁原发性血小板增多症女性患者,给予羟基脲0.5g口服,3次/d,灯盏花素50mg静脉滴注,1次/d,第4天羟基脲加量至1.0g,3次/d。用药5d后患者出现胸腹部淡红色皮疹,瘙痒难忍。停用灯盏花素,给予抗过敏治疗,因患者PLT已由1120×109/L降至489×109/L,羟基脲减量至0.5g,3次/d。1周后,患者皮疹明显加重,融合呈大片,迁延至腰背、双髋及四肢。遂停用羟基脲,继续给予抗过敏治疗,皮疹逐渐消退。以后给予灯盏花素静脉滴注,未再出现皮疹。
1 female 80-year-old woman with essential thrombocythemia given orally 0.5g hydroxyurea orally, 3 times / d, breviscapine 50mg intravenous infusion, 1 / d, the amount of hydroxyurea on the 4th day to 1.0g, 3 Times / d. 5d after treatment, patients with chest and abdomen pink rash, itching unbearable. Breviscapine was discontinued, given anti-allergy treatment, because patients with PLT has been reduced from 1120 × 109 / L to 489 × 109 / L, hydroxyurea reduction to 0.5g, 3 times / d. After 1 week, the patient’s rash was significantly aggravated. The fusion was large and extended to the lower back, double hip and extremities. Then use hydroxyurea, continue to give anti-allergy treatment, the rash subsided. After given breviscapine intravenous infusion, there is no recurrence of rash.